Download PDF
Thromb Haemost 1966; 15(03/04): 491-500
DOI: 10.1055/s-0038-1649451
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

The In-Vivo-Effect of E-Aminocaproic Acid (EACA) on Human Plasma Fibrinolytic System

St Niewiarowski
1   Department of Physiological Chemistry, Medical School, Bialystok. Poland
,
Nina Wołosowicz
1   Department of Physiological Chemistry, Medical School, Bialystok. Poland
› Author Affiliations
Further Information

Publication History

Publication Date:
27 June 2018 (online)

Also available at
    Permissions and Reprints

Summary

EACA was administered orally to 30 healthy volunteers in a single doses of 0.1 g per kg body weight. The level of this compound in blood plasma and its effect on the human plasma fibrinolytic system were investigated.

EACA is rapidly absorbed from the intestinal tract, its maximal level in the blood plasma being reached one hour later. The half life of this compound in the blood plasma amounted to two hours on the average.

The following changes in the plasma fibrinolytic system were observed : a) an inhibition of euglobulin fibrinolysis, which was most pronounced three hours after EACA ingestion ; b) a considerable increase in plasminogen, antiplasmin and antitrypsin activities (maximum-five hours after EACA) ; c) slight increase in fibrinogen level (maximum-five hours after EACA).

The conclusion has been reached that EACA induces a rise in endogenous inhibitors of the fibrinolytic system in the normal organism which may reinforce the hemostatic effect of this drug. The observed phenomena may be explained if we assume that the activation of the fibrinolytic system in the organism is continuous.

 

  • References

  • 1 Ablondi F. B, De Renzo E. G. Mechanism of Clot Lysis by streptokinase and effects of epsilon-aminocaproic acid. Proc. Soc. exp. Biol. (N. Y) 102: 717 1959;
    CrossrefPubMedGoogle Scholar
  • 2 Alkjaersig N, Fletcher A. P, Sherry S. E-amino caproic acid: an inhibitor of plasminogen activation. J. biol. Chem 234: 832 1959;
    PubMedGoogle Scholar
  • 3 Amris A, Amris G. J. Turnover and distribution of 131iodine labelled human fibrinogen. Thrombos. Diathes. haemorrh. (Stuttg) 11: 404 1964;
    PubMedGoogle Scholar
  • 4 Anderson L. Studies on fibrinolysis in urinary tract disease and its treatment with epsilonaminocaproic acid. Acta chir. scand. suppl. 301 1962;
    PubMedGoogle Scholar
  • 5 Bar-Prcitkowska J, Niewiarowska M, Dobraczynska J. Zastosowanie kwasu E-amino - kapronowego w ginekologii i poloznictwie. Ginek. pol 35: 81 1964;
    PubMedGoogle Scholar
  • 6 Blix S. The euglobulin method for estimation of fibrinolytic activity in streptokinase - activated plasma. Scand. J. clin. Lab. Invest 14: 528 1962;
    CrossrefPubMedGoogle Scholar
  • 7 Biduk K, Furman M. On the controlling function of the kidneys in fibrinolysis. Experientia (Basel) 18: 146 1962;
    CrossrefPubMedGoogle Scholar
  • 8 Buluk K, Malofiejew M. Otrzymywanie aktywatora fibrynolizy w nerce poza ustrojem (aktywator fibrynolizy w izolowanej nerce). Acta physiol, pol 14: 371 1963;
    PubMedGoogle Scholar
  • 9 Celander D. R, Dale M, Guest M. M. The fibrinolytic system: a review of its therapeutic significance and control with particular emphasis on its inhibition by E-aminocaproic acid. Tex. Rep. Biol. Med 19: 16 1961;
    PubMedGoogle Scholar
  • 10 Deutsch E, Marschner I. Antifibrinolysine. Folia haematol. N.F 08: 74 1963;
    PubMedGoogle Scholar
  • 11 Gajewski J, Alexander B. Effect of epsilonaminocaproic acid on the turnover of labelled fibrinogen in rabbits. Circulât. Res 13: 432 1963;
    PubMedGoogle Scholar
  • 12 KeJcwicJc R. A, Mackay M. E, Nance H. M, Record B. R. The purification of human fibrinogen. Biochem. J 60: 671 1955;
    PubMedGoogle Scholar
  • 13 Kostro B, Prokopowicz J, Serwatko A. Badanie ostrej i przewleklej toksycznosci kwasu E-aminokapronowego. Acta physiol, pol 15: 439 1964;
    PubMedGoogle Scholar
  • 14 Kowalski E, Kopec M, Niewiarowski S. Evaluation of the euglobulin method of determination of fibrinolysis. J. clin. Path 12: 215 1959;
    CrossrefPubMedGoogle Scholar
  • 15 Lewis J. H. Effects of epsilon amino caproic acid (EACA) on survival of fibrinogen I131 and on fibrinolytic and coagulation factors in dogs. Proc. Soc. exp. Biol. (N. Y) 114: 777 1963;
    CrossrefPubMedGoogle Scholar
  • 16 Lewis J. H, Ferguson J. H. Partial purification of human prothrombin and proconvertin, their characteristics and interaction. J. clin. Invest 32: 915 1953;
    CrossrefPubMedGoogle Scholar
  • 17 Lewis J. H, Doyle A. P. Effects of epsilon aminocaproic acid on coagulation and fibrinolytic mechanisms. J. Amer. med. Ass 188: 56 1964;
    PubMedGoogle Scholar
  • 18 Mc G. P.Nicol. Disordered fibrinolytic activity and its control. Scot. med. J 07: 266 1962;
    PubMedGoogle Scholar
  • 19 McNicol G. P, Fletcher A. P, Alkjaersig N, Sherry S. The absorption, distribution, and. excretion of E-aminocaproic acid following oral or intravenous administration to man. J. Lab. clin. Med 59: 15 1962;
    PubMedGoogle Scholar
  • 20 Müllertz S. The plasmin activator system in human blood. Thrombosis and Embolism Proc. 1st Int. Conf.. Basel; 1954: 79.
    Google Scholar
  • 21 Niewiarowska M, Mçgrzynowicz Z. Influence of dicoumarol derivatives on plasma fibrinolytic system. Thrombos. Diathes. haemorrh. (Stuttg) 03: 279 1959;
    PubMedGoogle Scholar
  • 22 Niewiarowski S. L’adsorption des facteurs du systeme fibrinolytique par la bentonite. Path. Biol 07: 2557 1959;
    PubMedGoogle Scholar
  • 23 Niewiarowski S. Untersuchungen über die hämostatische Wirkung von E - Aminokapr on - säure (EACA). Z. ges. inn. Med 20: 323 1965;
    PubMedGoogle Scholar
  • 24 Niewiarowski S, Prokopowicz J, Poplawski A, Worowski K. Inhibition of dog fibrinolytic system in experimental tubular necrosis of kidney. Experientia (Basel) 20: 101 1964;
    CrossrefPubMedGoogle Scholar
  • 25 Nilsson I. M, Sjoerdsma A, Waldenstrom J. Antifibrinolytic activity and metabolism of E-aminocaproic acid in man. Lancet 1322 1960;
    PubMedGoogle Scholar
  • 26 Nilsson I. M, Björkman S. E, Andersson L. Clinical experiences with E-aminocaproic acid (EACA) as an antifibrinolytic agent. Acta med. scand 170: 487 1961;
    PubMedGoogle Scholar
  • 27 Norman P. S. Studies of the plasmin system. II. Inhibition of plasmin by serum or plasma. J. exp. Med 108: 53 1958;
    PubMedGoogle Scholar
  • 28 Norman P. S, Hill B. M. Studies of the plasmin system. III. Physical properties of two inhibitors in plasma. J. exp. Med 108: 639 1958;
    PubMedGoogle Scholar
  • 29 Okamoto S. Plasmin and antiplasmin. Their pathologic physiology. Keio J. Med 08: 211 1959;
    PubMedGoogle Scholar
  • 30 Paraskewas M, Nilsson I. M, Martinson G. A method for determining serum inhibitors of plasminogen activation. Scand. J. clin. Lab. Invest 14: 138 1962;
    CrossrefPubMedGoogle Scholar
  • 31 Quick A. J. Hemorrhagic Diseases. Lea and Febiger. Philadelphia; 1954
    Google Scholar
  • 32 Sato S, Ishibashi Y, Endo T, Watanabe K, Nakajima K. Clinical use of E-Amino-N-Caproic acid on methropathia haemorrhagica. Keio J. Med 08: 267 1959;
    CrossrefPubMedGoogle Scholar
  • 33 Schnitze H. E, Heimburger N, Heide K, Haupt H, Storiko K, Schwick H. G. Preparation and characterization of o^-trypsin inhibitor and a2-plasmin inhibitor of human serum. Proc. 9th Congr. europ. Soc. Haemat., Lisbon.. 1963: 1315 Karger, Basel.:
    Google Scholar
  • 34 Wolosowicz N, Niewiarowski S, Czerepko K. Method for determining E-Aminocaproic Acid (EACA) in blood plasma, based on the antifibrinolytic properties of this compound. Thrombos. Diathes. haemorrh. (Stuttg) 10: 309 1964;
    PubMedGoogle Scholar
  • 35 Worowski K. Unpublished experiments..
    PubMedGoogle Scholar
  • 36 Worowski K, Niewiarowski S, Prokopowicz J. Fibrinolysis and fibrinogen breakdown products (antithrombin VI) in renal venous blood (RVB) in dog. Thrombos. Diathes. haemorrh. (Stuttg) 12: 87 1964;
    PubMedGoogle Scholar
  • 37 Zylber J, Blatt W. F, Jensen H. Mechanism of bovine plasminogen activation by human plasmin and streptokinase. Proc. Soc. exp. Biol. (IST. Y) 102: 755 1959;
    CrossrefPubMedGoogle Scholar